A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK

Journal of Medical Economics

Volumn 7, Issue 29-40, 2004, Pages 29-40

  Remák, Edit ^a   Hutton, John ^a   Selai, Caroline E ^b   Trimble, Michael R ^b   Price, Martin J ^c  

^a MEDTAP International Inc   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Janssen Cilag   (United Kingdom)

Author keywords

Adjunctive treatment; Antiepileptic drugs; Bootstrapping; Cost utility analysis

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PIRACETAM; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; CHILD; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; OUTCOMES RESEARCH; PRESCRIPTION; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCORING SYSTEM; SIDE EFFECT; WELLBEING;

EID: 3142663909     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200407029040     Document Type: Review

References (22)

1. NICE. Health technology appraisal scope document. Newer drugs for adults with epilepsy: London, National Institute for Clinical Excellence, 2002.
2. Heaney DC, Begley CE. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 2002; 43 (Suppl 4): 10-17.
3. Loomes G, McKenzie L. The use of QALYs in health care decision making. Social Science and Medicine 1989; 28: 299-308.
4. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8: 8-13.
5. Selai CE, Trimble MR. Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value? Seizure 1998; 7: 417-418.
6. O'Donoghue MF, Duncan JS, Sander JWAS. The National Hozpital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale. Epilepsia 1996; 37: 563-571.
7. Kendrick AM, Trimble MR. Repertory grid in the assessment of quality of life in patients with epilepsy: the Quality of Life Assessment Schedule. In Trimble MR, Dodson WE, Eds. Epilepsy and the Quality of Life. New York, Raven Press, 1994.
8. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
9. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 44. London, 2002.
10. Netten A, Curtis L. Unit costs of health and social care 2002. University of Kent, Canterbury. Personal Social Services Research Unit, 2002.
11. The Chartered Institute of Public Finance and Accountancy (CIPFA). The health service financial database and comparative tool, 2001. Institute of Public Finance Limited, Croydon, 2001.
12. Dolan P, Gudex C, Kind P, Williams A. A social tariff for Euroqol; results from a UK general population study. Discussion paper 138. University of York, Centre for Health Economics, York, 1995.
13. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics 1997; 6: 327-340.
14. Briggs AH, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions. Drug Information Journal 2001; 35: 1455-1468.
15. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 2001; 10: 779-787.
16. Selai C, Kaiser S, Trimble M, Price M. Evaluation of the relationship between epilepsy severity and utility [Abstract] Value in Health 2002; 5: 512-513.
17. CareLine Information Centre for Wandsworth, http://www.careline.org.uk. Date accessed: 15 May 2003.
18. University College London Hospitals NHS Trust Provider to Provider Tariff 2002-2003, http://www.uclh.org. Date accessed: 15 May 2003.
19. NHS Reference Costs 2002, http://www.doh.gov.uk/nhsexec/refcosts.htm.
20. OMNILABS (UK) Limited. Directory and price list, October 2000.
21. van Hout BA, Gagnon DD, McNulty P, O'Hagan A. The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data - A first approximation. Pharmacoeconomics 2003; 21: 315-326.
22. Stavem K, Bjørnæs H, Lossius MI. Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy. Epilepsy Research 2001; 44: 179-189.